2014
DOI: 10.4172/1747-0862.1000125
|View full text |Cite
|
Sign up to set email alerts
|

Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
4
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 97 publications
0
4
0
Order By: Relevance
“…A decrease in pulmonary MMP protein levels usually accompanies increased PAI-1 protein levels, which ultimately leads to increased ECM deposition and chronic fibrosis (35)(36)(37)(38). Because MMP2 and MMP9 share similar substrates, the Lungs from both female and male mouse offspring (6-wk old) from mothers prenatally exposed to e-cig aerosols with or without nicotine were homogenized, and ECM-related protein markers were analyzed by Western blot.…”
Section: Discussionmentioning
confidence: 99%
“…A decrease in pulmonary MMP protein levels usually accompanies increased PAI-1 protein levels, which ultimately leads to increased ECM deposition and chronic fibrosis (35)(36)(37)(38). Because MMP2 and MMP9 share similar substrates, the Lungs from both female and male mouse offspring (6-wk old) from mothers prenatally exposed to e-cig aerosols with or without nicotine were homogenized, and ECM-related protein markers were analyzed by Western blot.…”
Section: Discussionmentioning
confidence: 99%
“…The development of synthetic PAI-1 inhibitors has focused on their potential utility as antithrombotic agents or as a treatment option for acute and chronic fibrotic disease (Brown 2010). Over the last 20 years, several low molecular weight PAI-1 antagonists have been developed and tested in vitro, in animal models in vivo, and in clinical trials (Brown 2010;Simone et al 2014). Indeed, the available data suggest that inhibitory approaches directed to PAI-1 SERPIN activity may well be a promising therapeutic strategy to limit vascular fibrosis, reduce tumor aggressiveness, reduce airway remodeling in a model of chronic asthma, and promote regenerative tissue repair.…”
Section: Discussionmentioning
confidence: 99%
“…A highly-interactive plasmin-matrix metalloproteinase (MMP) pericellular proteolytic cascade is finely “titrated” both temporally and spatially by SERPINE1 (PAI-1). This complex cooperating system of proteases and inhibitors is fundamental to normal tissue repair and development of chronic diseases (adapted from [ 11 ]).…”
Section: Figurementioning
confidence: 99%